Business
Obagi Medical and Next Health Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™
Next Health selected as a leading wellness and longevity partner given its innovative approach to personalized aesthetics and health optimization NEW YORK and
About this update from Waldencast Plc
[{"type":"text","content":"Next Health selected as a leading wellness and longevity partner given its innovative approach to personalized aesthetics and health optimization\nNEW YORK and LOS ANGELES, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Next Health as a key partner in the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Next Health was selected for its pioneering commitment to longevity, personalized wellness, and cutting-edge aesthetic treatments across its growing network of health optimization centers. Through this real-world evaluation collaboration, Next Health will conduct a structured, multi-site assessment of Obagi® saypha® MagIQ™ within its practices. The program will leverage Next Health’s expertise in integrating advanced injectables with holistic protocols, patient-centric education, and data-driven outcomes to generate meaningful real-world evidence on the filler’s performance in wellness-focused environments. “At Next Health, we’re dedicated to pushing the boundaries of longevity and aesthetic medicine through innovative, evidence-based approaches,” said Dr. Milan Shah, Director of Aesthetics at Next Health. “Obagi’s ALOHA Program aligns perfectly with our mission to deliver transformative results by combining high-performance injectables like saypha® MagIQ™ with comprehensive skincare and wellness strategies. This partnership allows us to contribute real-world insights that elevate patient care and outcomes across our network.” The ALOHA Program evaluates both clinical efficacy and patient experience while equipping providers with integrated Obagi protocols to enhance satisfaction, loyalty, and consistent results. Standardized data will be collected across participating Next Health locations, with initial findings to be shared at upcoming Next Health leadership meetings and presented at major industry conferences to showcase the impact of this new injectable in a longevity and optimization setting. “Collaborating with forward-thinking leaders like Next Health reinforces Obagi’s dedication to launching aesthetics solutions supported by robust, practice-based evidence,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA program ...